Next Article in Journal
Use of Heated Tobacco Products within Indoor Spaces: Findings from the 2018 ITC Japan Survey
Previous Article in Journal
Using a Developmental-Relational Approach to Understand the Impact of Interpersonal Violence in Women Who Struggle with Substance Use

Int. J. Environ. Res. Public Health 2019, 16(23), 4863; https://doi.org/10.3390/ijerph16234863

Article
Lack of Association between Cytokine Genetic Polymorphisms in Takayasu’s Arteritis in Mexican Patients
1
Immunology Department, Instituto Nacional de Cardiología “Ignacio Chávez”. Juan Badiano No. 1, Col. Sección XVI, Tlalpan, México City 14080, Mexico
2
Physiology Department, Instituto Nacional de Cardiología “Ignacio Chávez”, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, Mexico City 14080, Mexico
*
Author to whom correspondence should be addressed.
Received: 11 October 2019 / Accepted: 27 November 2019 / Published: 3 December 2019

Abstract

:
Aim: To investigate the relation between polymorphisms in the interleukin 10 (IL)-10, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β and interferon (IFN)-γ genes and Takayasu’s arteritis in the Mexican population. Methods: A case-control study was performed to investigate the associations of IL-10, TNF-α, TGF-β and IFN-γ polymorphisms in a sample of 52 Takayasu’s arteritis patients, diagnosed according to the criteria of the American College of Rheumatology and EULAR PRINTO criteria when the patients were under 18 years of age; 60 clinically healthy unrelated Mexican individuals by the 5′ exonuclease TaqMan polymerase chain reaction. Polymorphic haplotypes were constructed after linkage disequilibrium analysis. Results: Significant differences were not found in the distribution for genotype and allele frequencies of the polymorphisms studied between healthy controls and Takayasu´s arteritis patients. Likewise, significant associations were not detected in the haplotype analysis with the different genes studied. Conclusions: These findings suggest that the polymorphisms in IL-10, TNF-α, TGF-β and IFN-γ might not contribute to the susceptibility of Takayasu´s arteritis in the Mexican population.
Keywords:
cytokines; Takayasu′s arteritis; polymorphisms; Mexican population

1. Introduction

Takayasu′s arteritis (TA) is an inflammatory disease that affects medium and large arteries, predominantly the aorta and its main branches. The arterial inflammation can lead to wall thickening, arterial stenosis, fibrosis, thrombus formation, and progressive occlusion [1]. The clinical manifestations of Takayasu´s arteritis usually appear in childbearing-age women [1,2].
Inflammation in Takayasu´s arteritis begins around the vasa vasorum and it is accompanied by the infiltration of several inflammatory cells, leading to granuloma formation. At this stage, the production of inflammatory mediators is markedly increased [3,4]. This response includes many factors such as CD4+/CD8+ lymphocytes, macrophages and pro-inflammatory cytokines.
Cytokines are involved in synergistic and antagonistic interactions, exhibiting both positive and negative regulatory effects [5]. Several studies have related single nucleotide polymorphisms (SNPs) of some cytokine genes to risk factors in inflammatory processes. The formation of granulomas in giant cell arteritis and vascular granulomatous are also related [6,7]. Among the cytokines that might be involved, tumor necrosis factor (TNF)-α, a powerful immunomediator and proinflammatory cytokine that influences a wide variety of adverse effects on the body’s cells, can activate growth factors, acting as a chemoattractant and affecting the synthesis of adhesion molecules.
Several studies have suggested that the expression of TNF-α is affected by polymorphisms in the promoter region of its gene, which has been identified at position-238 (rs361525) and-308 (rs1800629). These polymorphisms modify the production of the cytokine. On the other hand, transforming growth factor (TGF)-β is a cytokine that induces the de novo differentiation of IL-17-producing T cells in the presence of pro-inflammatory cytokine IL-6 and could also be altered in TA [7]. Interleukin (IL-10) is an important anti-inflammatory cytokine, which can be secreted by TH2 cells and macrophages, having powerful deactivation properties and anti-inflammatory effects, since it inhibits the synthesis of cytokines [8]. It has been reported that approximately 75% of the difference in IL-10 secretion is due to genetic factors and controlled at the transcriptional level [9]. Three SNPs (C-592A, C-819T, and G-1082A) in its promoter region have been associated with several diseases such as cardiovascular diseases; however, the results are not conclusive [10,11,12,13]. Interferon-gamma (IFN-γ) is produced by Th1-type CD4+ lymphocytes, CD8+ lymphocytes, and natural killer (NK) cells, and its function is focused on macrophage inflammation intervention [14,15].
Thus, the aim of our study was to determine whether polymorphisms in the IL-10, TNF-α, TGF-β and IFN-γ genes are associated with the development of TA in patients, comparing these polymorphisms to those found in healthy individuals.

2. Materials and Methods

2.1. Subjects

All participants or their guardians provided a written informed consent form prior to the study. The study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the Instituto Nacional de Cardiología “Ignacio Chávez” (Ethical approval number: 10-678).
The selection of patients diagnosed with Takayasu’s arteritis was carried out by the criteria of the American College of Rheumatology and then classified according to the criteria proposed by Hata et al. [16] into 5 subtypes: (1) patients with aortic arch involvement were considered as type I; (2) patients in which the lesion was limited to the ascending aorta and the aortic arch were considered as type IIa; patients in which the lesion also included the descending aorta without involvement of the celiac artery were considered as type IIb; (3) patients in which the lesion involved the descending aorta (from the end of the aortic arch to the femoral artery) were considered as type III (4) patients with damage to the abdominal aorta and renal arteries were classified as type IV; (5) patients with involvement of the entire aorta and its branches were classified as type V. In each type, coronary and pulmonary arteries may be involved. [16,17].
For children aged 18 years or younger, we used EUKAR PRINTO criteria: classification of TA required typical angiographic abnormalities of the aorta or its main branches and pulmonary arteries (mandatory criterion) plus one of five criteria—(1) pulse deficit or claudication; (2) blood pressure discrepancy in any limb; (3) bruits; (4) hypertension; (5) elevated acute phase reactant [18].
In addition, 60 clinically healthy patients were studied. These subjects were without any kinship and were recruited at the National Cardiology Institute ¨Ignacio Chávez¨ in Mexico City. The inclusion criteria for control subjects were: normal parameters of body mass index (BMI) and plasma lipid levels, absence of hypertension, familial histories of type 2 diabetes mellitus, coronary heart disease or inflammatory-associated diseases.
For all participants, blood pressure was measured after 5 min in a sitting position. The criteria for hypertension was the following; diastolic pressure above 90 mmHg and systolic pressure above 140 mmHg in at least three recordings on different days.
The National Institute of Cardiology “Ignacio Chávez” is a reference center for Takayasu’s arteritis. Consequently, the patients came from different states in Mexico. All participants were unrelated and were of Mexican Mestizo descent—i.e., the individual and the last three generations of their family were born in Mexico. A Mexican Mestizo is defined as someone born in Mexico, who is a descendant of the original native inhabitants of the region and individuals, mainly Spanish, of Caucasian and/or African origin, who arrived in America during the sixteenth century.

2.2. DNA Preparation

Genomic DNA was extracted from whole blood containing EDTA by standard techniques. The IL-10 −1082 A/G (rs1800896), IL-10 −819 C/T (rs1800871), IL-10 −592 A/C (rs1800872), TNF-α −238 A/G (rs361525), TNF-α −308 A/G (rs1800629), IFN-γ −179 G/T (rs2069709), IFN-γ −155 G/A (rs2069710), TGF-β −509 T/C (rs1800469) and TGF-β 29 T/C (rs1800470) SNPs were genotyped using 5′ exonuclease TaqMan genotyping assays on a 7900HT Fast real-time PCR system, according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). Each SNP (allele and genotype) was manually and automatically defined with allelic discrimination software (7300 System SDS Software® by Applied Biosystems, Foster City, CA, USA) (Table 1).

2.3. Statistical Analysis

All calculations were performed using SPSS version 18 (SPSS Chicago, Il, USA) and EPISTAT statistical program (Version 5.0; USD Incorporated 1990, Stone Mountain, Georgia).
The p values were corrected (pC) according to the number of specificities tested and the number of comparisons performed, and they were considered statistically significant if their value was <0.05. Relative risk with 95% confidence intervals (CI) was calculated as the odds ratio. Pairwise linkage disequilibrium (LD, D’) estimations between polymorphisms and haplotype reconstruction were performed with Haploview version 4.1 (Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA). Statistical significance was accepted at an alpha level of less than or equal to 0.05.

3. Results

A total of 112 subjects were analyzed, including 52 Takayasu´s arteritis patients according to the American College of Rheumatology criteria. Thirty-two subjects were in the active phase (61.5%) and 20 were in the nonactive phase (38.5%). Hypertension was present in 24 (46.1%) TA patients (one with type I Hata’s classification, three with type II and 20 with type V). The control group included 48 women and 12 men, with a mean age of 34.7 years and an range of 17–51 years. The demographic characteristics are shown in Table 2. The observed and expected frequencies in both groups were in the Hardy–Weinberg equilibrium, indicating that our population does not have co-dominance or linkage disequilibrium.
Table 3 summarizes the allele and genotype frequencies of the IL-101082 A/G (rs1800896), IL-10819 C/T (rs1800871), IL-10592 A/C (rs1800872), TNF-α238 A/G (rs361525), TNF-α308 A/G (rs1800629), IFN-γ179 G/T (rs2069709), IFN-γ155 G/A (rs2069710), TGF-β509 T/C (rs 1800469) and TGF-β 29 T/C (rs 1800470) genes in Takayasu’s arteritis and healthy control groups.
In the TNF-α gene in both studied polymorphisms (rs361525 and rs1800629), no homozygous individuals were found for the minor allele; the same was true for both the studied polymorphisms in IFN-γ (rs2069709 and rs2069710). In the case of TGF-β509 T/C (rs1800469), an increase in the frequency of the heterozygous genotype was observed. However, there was no statistical difference. On the other hand, in the analysis of IL-10 polymorphisms, (rs1800872) and IL-10819 C/T (rs1800871), the most frequent genotypes were heterozygous and, in both cases, the predominant allele was the C allele. For IL-1082 (rs1800896), the most frequent allele was the A allele. In all cases, none of the genotypes studied showed statistically significant differences between the two groups.
In addition, we analyzed other inheritance models (additive and recessive). For TGF-β509, p = 0.609 in the additive model, while p = 0.381 in the recessive model. For TGF-β, there were 29 values at p = 0.313 and p = 0.691, respectively. For IL-10592, in the additive model, p = 0.988, and p = 0.940 in the recessive model. For IL-10819, the value was p = 0.730 and p = 774, and p = 0.844 and p = 0.336 for IL-101082, respectively. Finally, after the construction of the haplotypes of the genes studied, it was only possible to observe the distribution of the IL-10, TNF-α and TGF-β genes (Table 4).
The association between genetic variants in IL-101082 A/G (rs1800896), IL-10819 C/T (rs1800871), IL-10592 A/C (rs1800872), TNF-α238 A/G (rs361525), TNF-α308 A/G (rs1800629), IFN-γ179 G/T (rs2069709), IFN-γ155 G/A (rs2069710), TGF-β509 T/C (rs 1800469) and TGF-β 29 T/C (rs 1800470) and TA was evaluated by investigating allele, genotype, and haplotype frequencies in patients in the active phase or non-active phase, different age onset and Hata’s classification. No significant differences were observed between TA patients in any of the aforementioned parameters.
In order to evaluate the effect of the genetic charge derived from ethnicity, a comparison was made between the allelic frequencies of our Takayasu’s patient group and other populations previously reported with healthy subjects (Table 5). A statistically significant difference was found in the three studied genotypes of IL-10 with respect to the populations of both Korea and Tunisia, while for TNF-α, there were differences with the population of Taiwan and with the population of Iran in TNF-α238 as well as in TGF-β29.

4. Discussion

Despite the various studies carried out, the etiological factors that lead to TA remain unknown. It has been suggested that the presence of both genetic and environmental autoimmune factors may play a role in inflammatory processes. This results in an immune response mediated by large cells. Inflammatory processes are regulated by a fine balance between the pro-inflammatory and anti-inflammatory cytokines in infectious and autoimmune diseases and have been reported in several studies [19,20,21,22]. Nevertheless, which of these components are present and how they can influence the progression of the lesions is not well known in Takayasu’s arteritis. In this study, we looked for a possible association between the polymorphisms in the IL-101082 A/G (rs1800896), IL-10819 C/T (rs1800871), IL-10592 A/C (rs1800872), TNF-α238 A/G (rs361525), TNF-α308 A/G (rs1800629), IFN-γ179 G/T (rs2069709), IFN-γ155 G/A (rs2069710), TGF-β509 T/C (rs 1800469) and TGF-β 29 T/C (rs1800470) genes and the development of Takayasu’s arteritis.
Some studies have attempted to explore the association of different diseases with pro-inflammatory and anti-inflammatory cytokines. Studies have shown that pro-inflammatory cytokines, such as TNF-α, play an important role in granuloma formation and blood levels of TNF are increased in TA patients [21]. Other studies have shown that IL-10 plays a crucial role in the regulation of inflammation.
IL-10 is a potent inhibitor in the synthesis of proinflammatory cytokines; it inhibits the action of macrophages and, as a consequence, suppresses the activation of Th1 cells and adhesion molecules. It is known that IL-10 and TNF-α have complex and predominantly opposing roles in inflammation [22,23]. A self-regulating circuit has been reported in which, TNF-α stimulates the production of IL-10, which, in turn, reduces the synthesis of TNF-α [24]. This mechanism plays a fundamental role in the inhibition of immune and inflammatory responses. Many functions of IL-10 focus on the inhibition of macrophage function, including cytotoxic activity and cytokine synthesis. Thus, a low expression of IL-10 has been related to the polymorphisms in the IL-10 gene (−1082 A/G, −819 T/C and −592 A/C) in patients with hypertension, myocardial infarction and coronary artery disease [10,25,26].TGF-β is a cytokine widely distributed throughout the body. It acts as a suppressor of cell proliferation and the migration of vascular smooth muscle cells, promoting cell differentiation and apoptosis, as well as production of the plasminogen activator inhibitor. It is thus suggested that TGF-β-1 is involved in the atherogenic process [27,28]. Reports indicate that polymorphisms (29 T/C and-509 T/C) result in an increase in the expression of the TGF-β-1 gene, which has been associated with a greater susceptibility to various diseases such as myocardial infarction, coronary heart disease, and others [29].
Interferon-gamma (IFN-γ) is a cytokine secreted by Th1 cells, and is considered as a pro-inflammatory cytokine. Its levels are elevated in many diseases such as rheumatoid arthritis [30,31,32]. Recently, the abnormal expression of INF-γ was reported to be associated with a variety of auto-inflammatory and immune diseases [13,14]. IFN-γ can activate inactive CD4+ cells to differentiate into Th1 cells and inhibit the proliferation of Th2.
This work did not find any association of these SNPs with TA in Mexicans patients. Although comparisons were made with different genetic models (dominant, codominant and recessive), no association was found among them. The same was found when performing the haplotype analysis. However, our frequencies—allelic and genotypic—were not significantly different when compared to the frequencies reported in other studies in the Mexican population [31,32]. However, many reports show discrepancies in the frequencies in certain polymorphisms with respect to our present results. For example, the allele frequency of the three polymorphisms studied for IL-10 was different in our study population in comparison to the frequency in a Korean population (p ≤ 0.001) [33]. A similar result was found when comparing our population against a Tunisian population [34]. These results indicate that the genetic charge given by ethnicity can be a predisposing factor to the disease, in addition to other factors such as age, sample size, diet or environmental factors including exposure to certain pathogens such as Mycobacterium tuberculosis. All of these factors may be contributing differently to Takayasu’s arteritis. There are studies in which the participation of these mycobacteria in the pathogenesis of the disease has been suggested [35]; nevertheless, there are still discrepancies.
On the other hand, it is known that histocompatibility genes have been associated with genetic susceptibility to develop Takayasu’s arteritis. Previous studies in our laboratory showed that human leukocyte antigens (HLA) −B39, B15 and B40 are frequent alleles in the Mexican Mestizo population. Subtypes are rare and apparently of recent generation in Mexico, probably by recombination events at the intron 2 level. Subtypes of these alleles appear to be different from those reported in other populations, mainly of Asian origin [36]. Further, the analysis of genes B * 5201 and B * 3902 were associated with amino acid residues of serine and glutamic acid, which may be involved in antigen binding in the HLA molecule. These data suggest that despite the heterogeneity of the HLA-B alleles, most share characteristic alleles of the populations of the American continent, which may explain the differences in the susceptibility to the disease depending on ethnic origin.
TA is an uncommon disease and the true incidence and prevalence is probably underestimated globally. That is probably why TA has been included within the “orphan” diseases. Globally, the estimated incidence is over 1.2–2.6 million per year and it is 100 times higher in Asian countries [37]. In Japan, for instance, one of the countries with a higher prevalence of TA, there is an estimated prevalence of 0.01%, [38]. In Mexico, TA is frequent and only the institutional prevalence is known. Multicentric studies are not feasible. However, the findings of this series provide information on the relevance of ethnicity for this disease and allow us to consider new hypotheses about the mechanisms of inflammatory damage. In previous studies, we found an association with the insertion sequences of the tuberculosis genome [39]. Therefore, we believe that this insertion can be a trigger for the immune response. We also know that the pattern of recognition receptors present in the cells participates in the innate immune system, identifying molecular patterns associated with microbial pathogens. Those associated with damage or danger give rise to the immune response. We believe that the present results add to the knowledge on triggering mechanisms for TA. Further studies are needed to allow us to determine the pathways of damage through inflammatory and anti-inflammatory cytokines, which do not appear to be the main source of perpetuity of the inflammatory response in TA.

5. Conclusions

In conclusion, our results suggest that polymorphisms in the IL-101082 A/G (rs1800896), IL-10819 C/T (rs1800871), IL-10592 A/C (rs1800872), TNF-α238 A/G (rs361525), TNF-α308 A/G (rs1800629), IFN-γ179 G/T (rs2069709), IFN-γ155 G/A (rs2069710), TGF-β509 T/C (rs 1800469) and TGF-β 29 T/C (rs 1800470) genes make no genetic contribution to the susceptibility of TA in the Mexican population. Taking into account the role of these cytokines in inflammatory processes may require additional studies. In addition to investigating the pathways of inflammation, such as oxidative stress or the route of arachidonic acid, the consideration of environmental factors such as previous exposure to infectious agents with a larger sample size needs to be further explored.

Author Contributions

M.E.S.: conceptualization, formal analysis and writing; C.H.-G.: conceptualization, methodology and investigation; Y.T.-P.: methodology and investigation; G.F.-Á.: methodology and investigation; R.G.: conceptualization, formal analysis, writing, review and editing.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Acknowledgments

We thank the participants of this study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Numano, F.; Okawara, M.; Inomata, H.; Kobayashi, Y. Takayasu’s arteritis. Lancet 2000, 356, 1023–1025. [Google Scholar] [CrossRef]
  2. Seyahi, E. Takayasu arteritis: An update. Curr. Opin. Rheumatol. 2017, 291, 51–56. [Google Scholar] [CrossRef] [PubMed]
  3. Inder, S.J.; Bobryshev, Y.V.; Cherian, S.M.; Wang, A.Y.; Lord, R.S.; Masuda, K.; Yutani, C. Immunophenotypic analysis of the aortic wall in Takayasu’s arteritis: Involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc. Surg. 2000, 8, 141–148. [Google Scholar] [CrossRef]
  4. Noguchi, S.; Numano, F.; Gravanis, M.B.; Wilcox, J.N. Increased levels of soluble forms of adhesion molecules in Takayasu arteritis. Int. J. Cardiol. 1998, 66, S23–S33. [Google Scholar] [CrossRef]
  5. Savioli, B.; Abdulahad, W.H.; Brouwer, E.; Kallenberg, C.G.M.; de Souza, A.W.S. Are cytokines and chemokines suitable biomarkers for Takayasu arteritis? Autoimmun. Rev. 2017, 1610, 1071–1078. [Google Scholar] [CrossRef]
  6. Weyand, C.M.; Younge, B.R.; Goronzy, J.J. IFN-γ and IL-17: The two faces of T-cell pathology in giant cell arteritis. Curr. Opin. Rheumatol. 2011, 231, 43–49. [Google Scholar] [CrossRef]
  7. Veldhoen, M.; Hocking, R.J.; Atkins, C.J.; Locksley, R.M.; Stockinger, B. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 242, 179–189. [Google Scholar] [CrossRef]
  8. Mallat, Z.; Besnard, S.; Duriez, M.; Deleuze, V.; Emmanuel, F.; Bureau, M.F.; Soubrier, F.; Esposito, B.; Duez, H.; Fievet, C.; et al. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 1999, 85, 17–24. [Google Scholar] [CrossRef]
  9. Anguera, I.; Miranda-Guardiola, F.; Bosch, X.; Filella, X.; Sitges, M.; Marín, J.L.; Betriu, A.; Sanz, G. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am. Heart J. 2002, 144, 811–817. [Google Scholar] [CrossRef]
  10. Lio, D.; Candore, G.; Crivello, A.; Scola, L.; Colonna-Romano, G.; Cavallone, L.; Hoffmann, E.; Caruso, M.; Licastro, F.; Caldarera, C.M.; et al. Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: Genetic background of male centenarians is protective against coronary heart disease. J. Med. Genet. 2004, 41, 790–794. [Google Scholar] [CrossRef]
  11. Rosner, S.A.; Ridker, P.M.; Zee, R.Y.L.; Cook, N.R. Interaction between inflammation-related gene polymorphisms and cigarette smoking on the risk of myocardial infarction in the Physician’s Health Study. Hum. Genet. 2005, 118, 287–294. [Google Scholar] [CrossRef] [PubMed]
  12. Nasibullin, T.R.; Timasheva, Y.R.; Tuktarova, I.A.; Érdman, V.V.; Nikolaeva, I.E.; Mustaphina, O.E. Combinations of cytokine gene network polymorphic markers as potential predictors of myocardial infarction. Russ. J. Genet. 2014, 50, 987–993. [Google Scholar] [CrossRef]
  13. Qi, X.F.; Feng, T.J.; Yang, P.; Feng, H.Y.; Zhang, P.; Kong, L.Y.; Liang, D.L.; Li, P.F.; Na, W.; Li, Y.W.; et al. Role of inflammatory parameters in the susceptibility of cerebral thrombosis. Genet. Mol. Res. 2014, 13, 6350–6355. [Google Scholar] [CrossRef] [PubMed]
  14. Prabhu Anand, S.; Harishankar, M.; Selvaraj, P. Interferon gamma gene +874A/T polymorphism and intracellular interferon gamma expression in pulmonary tuberculosis. Cytokine 2010, 492, 130–133. [Google Scholar] [CrossRef]
  15. Naderi Beni, F.; Fattahi, F.; Mirshafiey, A.; Ansari, M.; Mohsenzadegan, M.; Movahedi, M.; Pourpak, Z.; Moin, M. Increased production of nitric oxide by neutrophils from patients with chronic granulomatous disease on interferon-gamma treatment. Int. Immunopharmacol. 2012, 124, 689–693. [Google Scholar] [CrossRef]
  16. Hata, A.; Noda, M.; Moriwaki, R.; Numano, F. Angiographic findings of Takayasu arteritis: New classification. Int. J. Cardiol. 1996, 54, 155–163. [Google Scholar] [CrossRef]
  17. Dabague, J.; Reyes, P.A. Takayasu arteritis in Mexico: A 38-year clinical perspective through literature review. Int. J. Cardiol. 1996, 54, S103–S109. [Google Scholar] [CrossRef]
  18. Ozen, S.; Pistorio, A.; Iusan, S.M.; Bakkaloglu, A.; Herlin, T.; Brik, R.; Buoncompagni, A.; Lazar, C.; Bilge, I.; Uziel, Y.; et al. EULAR/PRINTO/PRES criteria for Henoch–Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann. Rheum. Dis. 2010, 69, 798–806. [Google Scholar] [CrossRef]
  19. Hutyrova, B.; Pantelidis, P.; Drabek, J.; Zurkova, M.; Kolek, V.; Lenhart, K.; Welsh, K.I.; du Bois, R.M.; Petrek, M. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2002, 165, 148–151. [Google Scholar] [CrossRef]
  20. Dewberry, R.; Holden, H.; Crossman, D.; Francis, S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2394–2400. [Google Scholar] [CrossRef]
  21. Park, M.C.; Lee, S.W.; Park, Y.B.; Lee, S.K. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatol. Oxf. 2006, 45, 545–548. [Google Scholar] [CrossRef] [PubMed]
  22. Cope, A.P. Regulation of autoimmunity by proinflammatory cytokines. Curr. Opin. Immunol. 1998, 10, 669–676. [Google Scholar] [CrossRef]
  23. LeBoeuf, R.C.; Schreyer, S.A. The role of tumor necrosis factor- receptors in atherosclerosis. Trends Cardiovasc. Med. 1998, 8, 131–138. [Google Scholar] [CrossRef]
  24. Van der Poll, T.; Jansen, J.; Levi, M.; ten Cate, H.; ten Cate, J.W.; van Deventer, S.J.H. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J. Exp. Med. 1994, 180, 1985–1988. [Google Scholar] [CrossRef] [PubMed]
  25. Girndt, M.; Köhler, H. Interleukin IL-10: An update on its relevance for cardiovascular risk. Nephrol. Dial. Transplant. 2003, 18, 1976–1979. [Google Scholar] [CrossRef]
  26. Koch, W.; Kastrati, A.; Bittiger, C.; Mehilli, J.; von Beckerath, N.; Schomig, A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001, 159, 137–144. [Google Scholar] [CrossRef]
  27. Kojima, S.; Harpel, P.C.; Rifkin, D.B. Lipoproteina. inhibits the generation of transforming growth factor-B: And endogenous inhibitor of smooth muscle cell migration. J. Cell. Biol. 1991, 113, 1439–1445. [Google Scholar] [CrossRef]
  28. Agrotis, A.; Bobik, A. Vascular remodeling and molecular biology: New concepts and therapeutic possibilities. Clin. Exp. Pharmacol. Physiol. 1996, 23, 363–368. [Google Scholar] [CrossRef]
  29. Mitsuhiro, Y.; Ichihara, S.; Lin, T.L.; Nakashima, N.; Yamada, Y. Association of T29 > C polymorphism of the transforming growth factor-B1 gene with genetic susceptibility to myocardial infarction in Japanese. Circulation 2000, 101, 2783–2787. [Google Scholar]
  30. Kim, E.Y.; Moudgil, K.D. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Citokine 2017, 98, 87–96. [Google Scholar] [CrossRef]
  31. Vargas-Alarcón, G.; Ramírez-Bello, J.; Juárez-Cedillo, T.; Ramírez-Fuentes, S.; Carrillo-Sánchez, S.; Fragoso, J.M. Distribution of the IL-1RN, IL-6, IL-10, IFN-γ, and TNF-α Gene Polymorphisms in the Mexican Population. Genet. Test. Mol. Biomark. 2012, 16, 1246–1253. [Google Scholar] [CrossRef] [PubMed]
  32. Cruz, M.; Fragoso, J.M.; Álvarez-León, E.; Escobedo-de-la-Peña, J.; Valladares, A.; Juárez-Cedillo, T.; Pérez-Méndez, O.; Vargas-Alarcón, G. The TGF-B1 and IL-10 gene polymorphisms are associated with risk of developing silent myocardial ischemia in the diabetic patients. Immunol. Lett. 2013, 156, 18–22. [Google Scholar] [CrossRef] [PubMed]
  33. Yu, G.I.; Cho, H.C.; Cho, Y.K.; Park, H.S.; Yoon, H.J.; Kim, H.S.; Nam, C.W.; Kim, Y.N.; Kim, K.B.; Ha, E.; et al. Association of promoter region single nucleotide polymorphisms at positions -819C/T and -592C/A of interleukin 10 gene with ischemic heart disease. Inflamm. Res. 2012, 618, 899–905. [Google Scholar] [CrossRef] [PubMed]
  34. Ben-Hadj-Khalifa, S.; Ghazouani, L.; Abboud, N.; Ben-Khalfallah, A.; Annabi, F.; Addad, F.; Almawi, W.Y.; Mahjoub, T. Functional interleukin-10 promoter variants in coronary artery disease patients in Tunisia. Eur. Cytokine Netw. 2010, 21, 136–141. [Google Scholar]
  35. Soto, M.E.; Soto, V.; Martín-Sandría, J.V.; Gamboa, R.; Huesca, C. Mycobacterium tuberculosis in the aorta of a patient with Takayasu’s arteritis. Extra pulmonary tuberculosis. Health 2012, 3, 159–161. [Google Scholar] [CrossRef]
  36. Vargas-Alarcon, G.; Zuñiga, J.; Gamboa, R.; Hernandez-Pacheco, G.; Hesiquio, R.; Cruz, D.; Martínez-Baños, D.; Portal-Celhay, C.; Granados, J.; Reyes, P.; et al. DNA sequencing of HLA-B in Mexican patients with Takayasu arteritis. Int. J. Cardiol. 2000, 75, S117–S122. [Google Scholar] [CrossRef]
  37. Sueyoshi, E.; Sakamoto, I.; Uetani, M. MRI of Takayasu’s arteritis: Typical appearances and complications. AJR Am. J. Roentgenol. 2006, 1876, W569–W575. [Google Scholar] [CrossRef]
  38. Terao, C. Revisited HLA and non-HLA genetics of Takayasu arteritis—Where are we? J. Hum. Genet. 2016, 61, 27–32. [Google Scholar] [CrossRef]
  39. Soto, M.E.; Del Carmen Ávila-Casado, M.; Huesca-Gómez, C.; Alarcón, G.V.; Castrejon, V.; Soto, V.; Hernandez, S.; Espinola-Zavaleta, N.; Vallejo, M.; Reyes, P.A.; et al. Detection of IS6110 and HupB gene sequences of Mycobacterium tuberculosis and bovis in the aortic tissue of patients with Takayasu’s arteritis. BMC Infect. Dis. 2012, 20, 194. [Google Scholar]
  40. Schotte, H.; Willeke, P.; Becker, H.; Poggemeyer, J.; Gaubitz, M.; Schmidt, H.; Schlüter, B. Association of extended interleukin-10 promoter haplotypes with disease susceptibility and manifestations in German patients with systemic lupus erythematosus. Lupus 2014, 23, 378–385. [Google Scholar] [CrossRef]
  41. Jamil, K.; Jayaraman, A.; Ahmad, J.; Joshi, S.; Shiva-Kumar, Y. TNF-alpha 308G/A and 238G/A polymorphisms and its protein network associated with type 2 diabetes mellitus. Sa. J. Biol. Sci. 2017, 24, 1195–1203. [Google Scholar] [CrossRef] [PubMed]
  42. Chiang, Y.C.; Kuo, L.N.; Yen, Y.H.; Tang, C.H.; Chen, H.Y. Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab. Comput Methods Programs Biomed 2014, 116, 319–327. [Google Scholar] [CrossRef] [PubMed]
  43. Ghamari, E.; Farnia, P.; Saif, S.; Marashian, M.; Ghanavi, J.; Farnia, P.; Velayati, A.A. Comparison of single nucleotide polymorphisms (SNP) at TNF-α promoter region with TNF receptor 2 (TNFR2) in susceptibility to pulmonary tuberculosis; using PCR-RFLP technique. Am. J. Clin. Exp. Immunol. 2016, 5, 55–61. [Google Scholar] [PubMed]
  44. Heidari, Z.; Mahmoudzadeh-Sagheb, H.; Ayub Rigi-Ladiz, M.; Taheri, M.; Moazenni-Roodi, A.; Hashemi, M. Association of TGF-β1 −509 C/T, 29 C/T and 788 C/T gene polymorphisms with chronic periodontitis: A case–control study. Gene 2013, 518, 530–534. [Google Scholar] [CrossRef]
  45. Wu, W.; Ding, Y.; Chen, Y.; Hua, Z.; Liu, H.; Wang, H.; Jiao, G. Susceptibility to ankylosing spondylitis: evidence for the role of ERAP1, TGFb1 and TLR9 gene polymorphisms. Rheumatol. Int. 2012, 32, 2517–2521. [Google Scholar] [CrossRef]
  46. Langdahl, B.L.; Carstens, M.; Stenkjaer, L.; Eriksen, E.F. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone 2003, 32, 297–310. [Google Scholar] [CrossRef]
  47. Chi-Huei, C.; Chiao-Hui, C.; Shiou-Ling, L. Transforming Growth Factor-b1 and Tumor Necrosis Factor-a are Associated with Clinical Severity and Airflow Limitation of COPD in an Additive Manner. Lung 2014, 192, 95–102. [Google Scholar]
  48. Rodríguez-Rodríguez, E.; Sánchez-Juan, P.; Mateo, I.; Llorca, J.; Infante, J.; García-Gorostiaga, I.; Berciano, J.; Combarros, O. Serum levels and genetic variation of TGF-b1 are not associated with Alzheimer’s disease. Acta. Neurol. Scand. 2007, 116, 409–412. [Google Scholar] [CrossRef]
  49. Qi, S.; Cao, B.; Jiang, M.; Xu, C.; Dai, Y.; Li, K.; Wang, K.; Ke, Y.; Ning, T. Association of the - 183 polymorphisms in the IFN-g gene promoter with hepatitis B virus infection in the Chinese population. J. Clin. Lab. Anal. 2005, 19, 276–281. [Google Scholar] [CrossRef]
  50. Chevillard, C.; Moukoko, C.E.; Elwali, N.E.; Bream, J.H.; Kouriba, B.; Argiro, L.; Rahoud, S.; Mergani, A.; Henri, S.; Gaudart, J. IFN-gamma polymorphisms (IFN-gamma + 2109 and IFN-gamma + 3810) are associated with severe hepatic fibrosis in human hepatic schistosomiasis (Schistosoma mansoni). J. Immunol. 2013, 171, 5596–5601. [Google Scholar] [CrossRef]
Table 1. Polymorphisms studied in Takayasu´s patients.
Table 1. Polymorphisms studied in Takayasu´s patients.
Gene LocalizationChromosomalGene NameTotal SNPs StudiedMarker (db SNP ID)Site Polymorphic
IL-101q31Interleukin-103rs1800896IL-10 −1082 A/G
rs1800871IL-10 −819 C/T
rs1800872IL-10 −592 A/C
TNF-α6p21Tumor necrosis factor-alpha2rs361525TNF-α −238 A/G
rs1800629TNF-α −308 A/G
IFN-γ12q15Interferon-gamma2rs2069709IFN-γ −179 G/T
rs2069710IFN-γ −155 G/A
TGF-β19q13.2Transforming growth factor beta2rs1800469TGF-β −509 T/C
rs1800470TGF-β 29 T/C
SNP—single nucleotide polymorphism; IL—interleukin; TNF—tumor necrosis factor; TGF—transforming growth factor, IFN—interferon gamma, db SNP ID—Database of Single Nucleotide Polymorphisms identification, A/G—adenine/Guanine, C/T—Cytosine/Thymine; rs—Reference SNP 2.3. Statistical Analysis
Table 2. Demographic characteristics of the study population.
Table 2. Demographic characteristics of the study population.
Demographic FeaturesTakayasu’s PatientsHealthy Controlsp
Total subjects (n)
Female50480.021 a
Male212
Age (years)2834.70.158 b
Medium(13–52)(17–51)
Hata’s classification (%)
Type I9.6-
Type II7.7-
Type III5.7-
Type IV0-
Type V76.9-
Activity (%)
Yes61.5-
No38.5-
Blood pressure (mmHg ± SD)
Diastolic82.93 ± 28.578.80 ± 9.60.068 c
Systolic140.34 ± 22.3122.61 ± 17.30.004 c
(mmHg) millimeter of mercury ± (SD) standard deviation; a chi square test; b Mann Whitney test; c T Student Test (t-test).
Table 3. Genotype and allele frequencies of the TNF-α, TGF-β, INF-γ and IL-10 polymorphisms in TA patients and controls.
Table 3. Genotype and allele frequencies of the TNF-α, TGF-β, INF-γ and IL-10 polymorphisms in TA patients and controls.
GeneGenotypeControlsPatientspOR (95% CI)
n%n%
TNF-α-238GG5998.34994.20.3350.271 (0.02–2.74)
GA11.735.80.3390.283 (0.02–2.76)
AA0000--
Alleles
G11999.110197.10.3390.282 (0.02–2.76)
A10.932.9--
TNF-α-308GG51854586.50.8191.000(0.40–2.45)
GA915713.50.9460.947 (0.55–1.60)
AA0000--
Alleles
G11192.59793.30.9701012 (0.40–3.18)
A97.576.7--
TGF-β-509TT1728.31121.10.5110.678 (0.28–1.62)
TC2338.82650.00.2931.608 (0.75–3.41)
CC2033.31528.80.7590.810 (0.36–1.81)
Alleles
T5747.54846.10.9460.947 (0.55–1.60)
C6352.55653.4--
TGF-β 29TT1728.31325.00.8540.843 (0.36–1.95)
TC2541.72751.90.3701.512 (0.71–3.19)
CC18301223.00.5410.700 (0.29–1.63)
Alleles
T5949.15350.90.8931.07 (0.63–1.81)
C6150.95149.1--
IFN-γ-179GG57955096.20.8691.315 (0.21–8.19)
GT3523.80.8690.760 (0.12–4.73)
TT0000--
Alleles
G11797.510298.10.8711.30 (0.21–7.98)
T32.521.9--
IFN-γ-155AA6010052100--
AG0000--
GG0000--
Alleles --
A120100104100--
G0000--
IL-10-592AA813.359.60.7510.691 (0.27–2.62)
AC30502853.80.8281.166 (0.55–2.45)
CC2236.71936.50.8550.994 (0.46–1.59)
Alleles
A4638.33836.50.8900.926 (0.53–1.59)
C7461.76663.5--
IL-10-819TT813.3611.51.0000.847 (0.27–2.62)
TC27452650.00.7341.222 (0.58–2.57)
CC2541.72038.50.8790.875 (0.40–1.86)
Alleles
T4335.83836.50.9761.031 (0.59–1.78)
C7764.26663.5--
IL-10-1082AA3253.32349.20.4400.693 (0.32–1.46)
AG2643.32751.90.4721.412 (0.66–2.97)
GG23.323.80.7151.160 (0.15–8.53)
Alleles
A90757471.11.6190.822 (0.45–1.48)
G30253028.9--
Note: OR—Odds risk, CI—Confidence interval.
Table 4. Haplotype distribution.
Table 4. Haplotype distribution.
IL-10Haplotype FrequencyTNF-αHaplotype FrequencyTGF-βHaplotype Frequency
CCA0.357GG0.911TC0.467
ATA0.352GA0.071CT0.435
CCG0.259 AG0.018CC0.065
ACA0.023 TT0.033
Table 5. Comparison between allele frequencies in different populations versus Takayasu’s arteritis.
Table 5. Comparison between allele frequencies in different populations versus Takayasu’s arteritis.
IL-10 −592pCOR (CI 95%)IL-10 −819pCOR (CI 95%)IL-10 −1082pCOR (CI 95%)
AC--TC--AG--
Our study36.563.5--36.563.5--71.128.9--
Korean [33]78.621.40.00010.20 (0.13–0.31)73.326.70.00010.20 (0.13–0.32)93.96.10.00010.16 (0.05–0.27)
Tunisian [34,35,36,37,38,39]20.0800.000396.9 (29.7–31.0)19.280.80.00022.12 (1.53–3.80)44.755.30.00013.10 (1.94–4.96)
German [40]28.271.80.10607.30 (2.20–24.1)28.271.80.10651.46 (0.94–2.25)54.745.30.00192.08 (1.32–3.20)
TNF-α −238 TNF-α −308
GApCOR (CI 95%)GApCOR (CI 95%)----
Our study97.12.9--93.76.7------
Indian [41]91.68.30.11173.06 (0.87–10.6)93.07.00.2232.53 (0.71–9.02)----
Taiwanese [42]82.117.80.00047.30 (2.20–24.1)98.61.40.6120.46 (0.09–2.34)----
Iranian [43]25.874.20.000196.9 (29.7–31.6)92.87.20.2132.62 (0.72–9.52)----
TGF-β −509 TGF-β −29
TCpCOR (CI 95%)TCpCOR (CI 95%)----
Our study46.156.4--50.949.10.0010-----
Iranian [44]39.860.20.34711.26 (0.80–0.09)31.069.00.80812.31 (1.42–3.76)----
Chinese [45]----48.951.10.91251.08 (0.69–1.70)----
Caucasian [46]----49.850.2-1.04 (0.68–1.61)----
Taiwanese [47]44.555.40.97260.97 (0.61–1.56)--------
Spanish [48]66.533.50.00010.43 (0.28–0.65)--------
IFN-γ −179 IFN-γ −155
GTpCOR (CI 95%)AGpC ----
Our study98.11.9--1000.0------
Chinese [49]----1000.0------
Sudanese [50]99.50.50.53830.24 (0.02–1.74)--------
pC—value p corrected, OR—Odds risk, CI: Confidence interval.
Back to TopTop